A Stronger Wegovy? What the 7.2 mg STEP UP Data Actually Says

"Stalled on 2.4. Can I just go higher?" Scroll the GLP-1 subreddits for ten minutes and you'll find that question asked a dozen ways, usually by someone whose scale stopped moving in month four. A trial finally tested exactly that — and the answer it brought back is more interesting than a clean yes.

The trial is STEP UP. It took semaglutide — the molecule inside Wegovy at its obesity dose — and pushed it to 7.2 mg, three times the approved 2.4 mg ceiling. Then it put that higher dose directly against the 2.4 mg most people are already on, and against placebo. The higher dose did win. But the whole story is in how much it won by, at what cost, and whether you can even get it. Short version: less than you'd hope, with a bigger gut tax, and no, not yet.

A bigger dose of the same molecule

Start with what 7.2 mg even is, because that framing changes how you read everything after it. This isn't a new drug. It's the same semaglutide you know as Wegovy, dialed up past the dose regulators have signed off on. The approved maximum for weight management is 2.4 mg a week. The 7.2 mg arm in STEP UP is that exact molecule at three times the dose — a research dose, not something sitting on a pharmacy shelf.

So when a headline calls it "stronger Wegovy," it's loose but not wrong. Stronger in the literal sense: more milligrams of the identical compound. The interesting question was never whether more drug does more — of course it tends to. It's whether the extra payoff justifies the extra everything-else. That's a thing you measure, not a thing you assume. STEP UP is the measurement.

How the trial was built

STEP UP was a phase 3b study, built the way a careful one should be: randomized, double-blind, and placebo-controlled. It enrolled adults living with obesity — a body mass index of 30 or higher — who did not have diabetes, and followed them for 72 weeks. In total, 1,407 people were randomly assigned: 1,005 to semaglutide 7.2 mg, 201 to semaglutide 2.4 mg, and 201 to placebo.

None of that is decoration. Double-blind means neither the participants nor the people running the trial knew who got which dose, which keeps hope and expectation out of the numbers. The 72-week window matters because weight loss on these medicines doesn't finish in a season — the curve keeps bending for the better part of a year and a half. And testing the new high dose against the approved one in the same study, on the same clock, is the only clean way to ask whether more is genuinely better.

That structure is what lets the comparison mean something. You're not stacking one study's high-dose number against a different study's standard-dose number and hoping they line up. Everyone walked the same 72 weeks under the same rules. When one arm beats another here, the gap is real — not an artifact of comparing this year's apples to last year's oranges.

The result: yes, more came off

Here's the number everyone's circling. Over 72 weeks, the mean change in body weight was an 18.7% loss with semaglutide 7.2 mg, a 15.6% loss with the approved 2.4 mg dose, and a 3.9% loss with placebo. So the higher dose did the thing you'd expect a higher dose to do. It moved the most.

Put it in body terms — with the caveat that the trial reported percentages, not kilograms, so this is just arithmetic to make the figures feel real. Start around 100 kg, and 18.7% is roughly 19 kg gone; 15.6% is closer to 16 kg. The placebo arm's 3.9% is the quiet reminder that structure alone — regular check-ins, someone keeping score — nudges the scale a little before any drug does its part.

The placebo result is the one people skip, and it's the one doing quiet work. A 3.9% drop with no active medicine is the baseline the drug has to clear to earn its credit. Everything semaglutide gets praised for is the distance above that line, not the whole number on its own.

A headline you caught somewhere might carry a figure larger than 18.7%. Trial numbers shift depending on how they're calculated and which window they cover, so it's easy for a rosier figure to circulate without the context that frames it. The 18.7% here is the trial's primary reported result, and it's the one to anchor on. When a bigger number floats by without its fine print, it isn't a lie — it's half a sentence.

But how much more, really

This is the part that reframes the rest. The 7.2 mg dose beat the approved 2.4 mg by an estimated 3.1 percentage points (95% confidence interval −4.7 to −1.6), and it beat placebo by 14.8 points (95% CI −16.2 to −13.4). Both gaps were statistically convincing — p sat below 0.0001 on each. So the higher dose genuinely separated from the standard one. That's not in dispute.

Now look at the size of it. You tripled the dose, from 2.4 mg to 7.2 mg, and the reward over the dose most people already take was 3.1 percentage points. Not 3.1 times the weight loss. About a fifth more, layered on top of what 2.4 mg was already delivering. That's the shape of diminishing returns: the first dose does the heavy lifting, and each step up after that buys a thinner slice.

Read those two rows together and the takeaway is hard to miss. Against placebo, 14.8 points is a large, unambiguous effect — that's the drug working, and it's why semaglutide is a big deal at all. Against the dose already in people's fridges, the bonus is 3.1 points. Both are real. Only one of them is the reason to reach for a needle three times stronger, and it's the smaller one.

The tradeoff: a heavier gut tax

A higher dose that came free of any extra cost would make this an easy call. It didn't. Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation, the familiar GLP-1 lineup — showed up more often the higher the dose climbed. They affected 70.8% of the 7.2 mg group, 61.2% of the 2.4 mg group, and 42.8% of the placebo group.

So the same step that bought 3.1 extra points of weight loss also raised the share of people dealing with stomach trouble by nearly ten points. There's the trade, laid bare: a little more off the scale, a little more queasiness on the way down. For some people that math works fine. For others, a rough week on 2.4 mg was already plenty.

Keep it in proportion, though. GI effects in this class tend to be heaviest early, while the body adjusts, and they skew mild-to-moderate rather than dangerous — the same arc anyone who's titrated from 0.25 up to 2.4 already knows. A high rate partly reflects careful counting, including a few off days that never became a real problem. Still, more than seven in ten isn't a footnote. It's the cost column to weigh honestly before deciding a bigger dose earns its place.

It isn't an approved dose yet

Here's the line that keeps everything above in proportion. As of 2026, semaglutide 7.2 mg is not an approved dose. The highest dose cleared for weight management is still 2.4 mg, the one already sold as Wegovy. The 7.2 mg arm lives inside a clinical trial and whatever regulatory review follows it — not on a prescription pad, and not at a pharmacy counter.

That matters for one blunt practical reason: you can't choose it. Whatever STEP UP showed, the higher dose isn't a setting your clinician can dial up today. So if a strong trial number tempts you to chase 7.2 mg through some gray-market route, the level answer is don't. There's no legitimate version of it to obtain, it hasn't cleared the safety and manufacturing bar that approval represents, and a good trial result is not the same thing as a regulator signing off.

So who might a higher dose actually suit

If the bonus is modest and the gut tax is real, is the higher dose pointless? Not necessarily — and this is where "it depends" earns its keep instead of being a dodge. For someone who tolerates 2.4 mg comfortably but has stalled well short of their goal, 3.1 extra points isn't nothing. On a 100 kg starting frame, that's roughly another 3 kg, and for the right person at the right plateau, that margin can matter.

But notice what the calculation rests on. It assumes you handle the higher dose without the stomach side becoming the whole story. The diminishing-returns curve and the climbing GI rate don't cancel each other out — they pull in opposite directions, and where you personally land depends on your own response and tolerance. No headline can hand you that. It's a conversation with a clinician who can see your history, your plateau, and how your gut managed the climb so far.

The trap is treating "stronger" as automatically "better for me." STEP UP doesn't say the highest dose is the right dose for everyone — it says a higher dose moves the average a bit more, at a cost, across a population. The right dose for one person is the one that fits their response and what their body will put up with, not the biggest one on the menu.

The safety lines that don't move with the dose

Some of semaglutide's fine print doesn't care how many milligrams you're taking. It rides along at every dose, and it's worth knowing now rather than later. Two pieces sit at the top.

First, the boxed warning. Semaglutide for weight management carries one for thyroid C-cell tumors — that's the United States FDA label talking, and approvals and labeling can read differently in other countries — and it's contraindicated, off the table entirely, for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If that history runs in your family, this whole drug class is a no, and it belongs at the very front of any conversation, before dose ever comes up.

Second, pancreatitis. Acute pancreatitis, including serious cases, has been seen in people on GLP-1 receptor agonists, semaglutide among them. The standard guidance is plain: if pancreatitis is suspected, the medicine is stopped. Persistent, severe abdominal pain isn't a side effect to ride out — it's a reason to call someone. None of this is a verdict that the drug is dangerous; it's the boundary fence that comes with it at any dose, 2.4 mg or 7.2 mg alike.

What this means if you're on Wegovy now

If you're already taking Wegovy and wondering whether you're suddenly on the weaker option, here's the calm read. You're not behind. The 2.4 mg you're on lost an average of 15.6% in this same trial — a large result by any measure, and most of the total effect the higher dose reached. The gap to 7.2 mg is 3.1 points, and that higher dose isn't available to you anyway right now.

So the move isn't to panic-shop for a stronger needle. If you've stalled, the productive conversation is about why — dose timing, the rest of the picture, whether your current dose still has room to work — not about leaping past the approved ceiling. And if a higher dose does eventually get approved, whether it suits you specifically will still come down to your response and your tolerance, not to a number you read in a feed. That's a discussion to bring to your next visit, not a decision to make from a headline.

Where that leaves the 7.2 mg question

Strip away the noise and STEP UP says something simple. Semaglutide 7.2 mg produced an 18.7% mean weight loss over 72 weeks, against 15.6% for the approved 2.4 mg dose and 3.9% for placebo. The higher dose won — by 14.8 points over placebo, and by 3.1 points over the dose most people already take. The price of that smaller margin was more gastrointestinal trouble, 70.8% versus 61.2%. And the whole thing rides inside a trial: 7.2 mg is not an approved dose, and 2.4 mg remains the ceiling you can actually get.

So "more dose, more loss" is true and also not the end of the sentence. The first 2.4 mg does most of the work; tripling it adds a real but modest sliver at a higher tolerance price. Stronger isn't automatically right for any one person — the right dose is the one that fits your response and what your body can handle. Everything here comes from published clinical-trial and peer-reviewed data, not from anyone's testimonial or sales pitch, and whether any of it fits your situation is a question for a clinician who can see the whole picture. That's exactly where a number like 18.7% deserves to be taken next.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app